27 September, 2022

Hyris to participate to SIBioC 2022 in Genova, presenting Hyris marketplace approach for laboratory medicine

From October 5th to October 7th, Hyris will be present at the SIBioC 2022 in Genova, to present Hyris marketplace approach and Hyris System^TM disruptive featuresfor laboratory medicine.

Our team will discuss with partners and prospects at Hyris stand First Floor, bar area.

Back to Latest frontpage

15 May 2024

Hyris signs a distribution agreement with GrowBIGogh

CONTINUE TO READING

20 February 2024

Hyris technology supports the fight against one of the world’s deadliest diseases, malaria.

CONTINUE TO READING

15 January 2024

Hyris fulfils its integration into Ulisse Biomed to give birth to a new international group ready to make its mark in the global biotech market.

CONTINUE TO READING

10 January 2024

Distribution agreement renewal with Biomol Laboratories, fostering the partnership in the field of personalised medicine

CONTINUE TO READING

04 December 2023

Hyris' signed a binding agreement for a reverse take-over, leading to a new integrated entity with Ulisse Biomed

CONTINUE TO READING

29 September 2023

Hyris' new onboarding programs support researchers and developers to launch testing kits.

CONTINUE TO READING

29 June 2023

Hyris Founder&CEO Stefano Lo Priore interviewed by Carter&Benson

CONTINUE TO READING

18 November 2022

Hyris and Singlabs signed a distributorship agreement for Singapore

CONTINUE TO READING

02 November 2022

Hyris and P.Intertrade Equipments signed a distributorship agreement for Thai market.

CONTINUE TO READING

27 September 2022

Hyris to participate to SIBioC 2022 in Genova, presenting Hyris marketplace approach for laboratory medicine

CONTINUE TO READING

15 May 2024

Hyris signs a distribution agreement with GrowBIGogh

CONTINUE TO READING

20 February 2024

Hyris technology supports the fight against one of the world’s deadliest diseases, malaria.

CONTINUE TO READING

15 January 2024

Hyris fulfils its integration into Ulisse Biomed to give birth to a new international group ready to make its mark in the global biotech market.

CONTINUE TO READING

10 January 2024

Distribution agreement renewal with Biomol Laboratories, fostering the partnership in the field of personalised medicine

CONTINUE TO READING

04 December 2023

Hyris' signed a binding agreement for a reverse take-over, leading to a new integrated entity with Ulisse Biomed

CONTINUE TO READING

29 September 2023

Hyris' new onboarding programs support researchers and developers to launch testing kits.

CONTINUE TO READING

29 June 2023

Hyris Founder&CEO Stefano Lo Priore interviewed by Carter&Benson

CONTINUE TO READING

18 November 2022

Hyris and Singlabs signed a distributorship agreement for Singapore

CONTINUE TO READING

02 November 2022

Hyris and P.Intertrade Equipments signed a distributorship agreement for Thai market.

CONTINUE TO READING

27 September 2022

Hyris to participate to SIBioC 2022 in Genova, presenting Hyris marketplace approach for laboratory medicine

CONTINUE TO READING

Solutions

Disruptive solutions for different sectors and use cases.

Hyris System™

The first multi-market platform able to deliver real value for the final customer, in a marketplace approach.

Partners

Hyris System™ allows a wide range of operators and researchers to develop their own assays and kits.

About Us

Hyris is a tech-bio company committed to democratise genetics and health insights.

Hyris signs a distribution agreement with GrowBIGogh

Hyris technology supports the fight against one of the world’s deadliest diseases, malaria.

Hyris fulfils its integration into Ulisse Biomed to give birth to a new international group ready to make its mark in the global biotech market.

Distribution agreement renewal with Biomol Laboratories, fostering the partnership in the field of personalised medicine

Hyris signs a distribution agreement with GrowBIGogh

Hyris technology supports the fight against one of the world’s deadliest diseases, malaria.

Hyris fulfils its integration into Ulisse Biomed to give birth to a new international group ready to make its mark in the global biotech market.

Distribution agreement renewal with Biomol Laboratories, fostering the partnership in the field of personalised medicine

Hyris' Solutions

Disruptive solutions for different sectors and use cases.

Hyris' Solutions

Disruptive solutions for different sectors and use cases.

Hyris System™

The first multi-market platform able to deliver real value for the final customer, in a marketplace approach.

Hyris System™

The first multi-market platform able to deliver real value for the final customer, in a marketplace approach.

Hyris Partners

Hyris System™ allows a wide range of operators and researchers to develop their own assays and kits.

Hyris Partners

Hyris System™ allows a wide range of operators and researchers to develop their own assays and kits.

Latest from Hyris

Discover Hyris recent stories, announcements, news, and much more.

Latests from Hyris

Discover Hyris recent stories, announcements, news, and much more.

About Us

Hyris is a tech-bio company committed to democratise genetics and health insights.

About Us

Hyris is a tech-bio company committed to democratise genetics and health insights.

Hyris to participate to SIBioC 2022 in Genova, presenting Hyris marketplace approach for laboratory medicine

Hyris signs a distribution agreement with GrowBIGogh

Hyris technology supports the fight against one of the world’s deadliest diseases, malaria.

Hyris fulfils its integration into Ulisse Biomed to give birth to a new international group ready to make its mark in the global biotech market.

Distribution agreement renewal with Biomol Laboratories, fostering the partnership in the field of personalised medicine

Hyris' signed a binding agreement for a reverse take-over, leading to a new integrated entity with Ulisse Biomed

Hyris' new onboarding programs support researchers and developers to launch testing kits.

Hyris Founder&CEO Stefano Lo Priore interviewed by Carter&Benson

Hyris and Singlabs signed a distributorship agreement for Singapore

Hyris and P.Intertrade Equipments signed a distributorship agreement for Thai market.

Hyris to participate to SIBioC 2022 in Genova, presenting Hyris marketplace approach for laboratory medicine

Hyris signs a distribution agreement with GrowBIGogh

Hyris technology supports the fight against one of the world’s deadliest diseases, malaria.

Hyris fulfils its integration into Ulisse Biomed to give birth to a new international group ready to make its mark in the global biotech market.

Distribution agreement renewal with Biomol Laboratories, fostering the partnership in the field of personalised medicine

Hyris' signed a binding agreement for a reverse take-over, leading to a new integrated entity with Ulisse Biomed

Hyris' new onboarding programs support researchers and developers to launch testing kits.

Hyris Founder&CEO Stefano Lo Priore interviewed by Carter&Benson

Hyris and Singlabs signed a distributorship agreement for Singapore

Hyris and P.Intertrade Equipments signed a distributorship agreement for Thai market.

Hyris to participate to SIBioC 2022 in Genova, presenting Hyris marketplace approach for laboratory medicine

Disruptive solutions
for different sectors and use cases.

Disruptive solutions
for different sectors
and use cases.

Disruptive solutions
for different sectors
and use cases.

The first multi-market platform
able to deliver real value
for the final customer,
in a marketplace approach.

The first multi-market platform
able to deliver real value
for the final customer,
in a marketplace approach.

Hyris System™ allows a wide range
of operators and researchers
to develop their own assays and kits.

Hyris System™ allows a wide range
of operators and researchers
to develop their own assays and kits.

Hyris is a tech-bio company
committed to democratise genetics
and health insights.

Hyris is a tech-bio company
committed to democratise genetics
and health insights.